Fondaparinux for DVT Prophylaxis

Standard Dosing Regimen

• The American College of Cardiology recommends a fixed dose of 2.5 mg subcutaneously once daily for all patients regardless of weight, for hospitalized medical patients, surgical patients, and cancer patients 1, 2, 3
• The American College of Surgeons suggests that surgical patients initiate the first dose 6-8 hours after surgery once hemostasis has been established, while medical patients begin immediately upon hospitalization 1, 2, 4

Duration of Prophylaxis

• The American Heart Association recommends continuing fondaparinux for the length of hospital stay or until fully ambulatory for medical patients, and a minimum of 7-10 days for surgical patients, with consideration for extended prophylaxis up to 4 weeks in high-risk patients 1, 2

Clinical Context and Patient Selection

• The American College of Chest Physicians states that fondaparinux is approved for hospitalized acutely ill medical patients with risk factors for VTE, patients undergoing major orthopedic surgery, patients undergoing non-orthopedic surgery, and cancer patients requiring thromboprophylaxis 1, 3, 4

Advantages Over Other Anticoagulants

• The European Society of Cardiology notes that fondaparinux has a once-daily dosing regimen, which improves compliance compared to twice or thrice-daily heparin regimens, and no routine monitoring is required due to predictable pharmacokinetics 5, 6, 7

Critical Contraindications and Precautions

• The National Kidney Foundation advises that fondaparinux is contraindicated in patients with severe renal impairment (creatinine clearance <20-30 mL/min) due to exclusive renal elimination, and dose reduction to 1.5 mg once daily may be considered for patients with CrCl 30-50 mL/min 6, 7, 5

Comparison with Alternative Agents

• The American College of Clinical Pharmacy suggests that fondaparinux may be preferred over low molecular weight heparin (LMWH) in patients with renal impairment (CrCl 30-50 mL/min) or a history of heparin-induced thrombocytopenia (HIT), while LMWH is generally preferred for long-term prophylaxis in cancer patients 4, 5, 2, 8

Safety Profile

• The European Heart Journal reports that major bleeding rates with fondaparinux are comparable to enoxaparin (1.3% vs 1.1%), and no routine coagulation monitoring or platelet count monitoring is required 6, 7, 5

Fondaparinux Prophylaxis in Overweight Adults

Dosing Strategy

Monitoring Requirements

Safety Profile

Alternative Agents in Specific Populations